MedTrace Logo

A 4 Week Study of Elidel (Pimecrolimus) for the Treatment of Seborrheic Dermatitis

NCT00403559 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 113

Last updated 2022-03-14

Study results available
· View outcomes & findings →

Summary

This is an exploratory study to determine effectiveness of Elidel for the treatment of seborrheic dermatitis

Conditions

  • Seborrheic Dermatitis

Interventions

DRUG

Elidel

DRUG

Ketoconazole Cream

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Dermatology Specialists Research

    lead OTHER

Principal Investigators

  • Steven Kempers, MD · Associated Skin Care Specialists

  • Bernard Goffe, MD · Dermatology Associates

  • Debra Breneman, MD · University of Cincinnati - Dermatology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-05-07
Primary Completion
2009-02-20
Completion
2009-02-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00403559 on ClinicalTrials.gov